DK3778897T3 - Immunonkolytiske terapier - Google Patents

Immunonkolytiske terapier Download PDF

Info

Publication number
DK3778897T3
DK3778897T3 DK20189155.3T DK20189155T DK3778897T3 DK 3778897 T3 DK3778897 T3 DK 3778897T3 DK 20189155 T DK20189155 T DK 20189155T DK 3778897 T3 DK3778897 T3 DK 3778897T3
Authority
DK
Denmark
Prior art keywords
immunocolitic
therapies
immunocolitic therapies
Prior art date
Application number
DK20189155.3T
Other languages
English (en)
Inventor
Stephen Howard Thorne
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Application granted granted Critical
Publication of DK3778897T3 publication Critical patent/DK3778897T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK20189155.3T 2013-08-22 2014-08-22 Immunonkolytiske terapier DK3778897T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361868978P 2013-08-22 2013-08-22
EP14837931.6A EP3036329B1 (en) 2013-08-22 2014-08-22 Immuno-oncolytic therapies

Publications (1)

Publication Number Publication Date
DK3778897T3 true DK3778897T3 (da) 2024-01-29

Family

ID=52484194

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14837931.6T DK3036329T3 (da) 2013-08-22 2014-08-22 Immunonkolytiske terapier
DK20189155.3T DK3778897T3 (da) 2013-08-22 2014-08-22 Immunonkolytiske terapier

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14837931.6T DK3036329T3 (da) 2013-08-22 2014-08-22 Immunonkolytiske terapier

Country Status (28)

Country Link
US (2) US11478518B2 (da)
EP (3) EP4324918A3 (da)
JP (3) JP6912199B2 (da)
KR (1) KR102389240B1 (da)
CN (1) CN105658795B (da)
AU (1) AU2014308648B2 (da)
CA (3) CA3213683A1 (da)
CY (1) CY1126587T1 (da)
DK (2) DK3036329T3 (da)
EA (1) EA037582B1 (da)
ES (2) ES2971528T3 (da)
FI (1) FI3778897T3 (da)
HR (1) HRP20240078T1 (da)
HU (1) HUE066593T2 (da)
IL (1) IL243996A0 (da)
LT (1) LT3778897T (da)
MD (2) MD4748C1 (da)
MX (1) MX2016002257A (da)
NZ (1) NZ716825A (da)
PE (1) PE20160673A1 (da)
PH (1) PH12016500329A1 (da)
PL (1) PL3778897T3 (da)
PT (1) PT3778897T (da)
RS (1) RS65104B1 (da)
SG (1) SG11201600960PA (da)
SI (1) SI3778897T1 (da)
SM (1) SMT202400047T1 (da)
WO (1) WO2015027163A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308648B2 (en) 2013-08-22 2020-11-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-oncolytic therapies
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
JP6452266B2 (ja) * 2015-07-22 2019-01-16 国立大学法人鳥取大学 ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子
HK1255192A1 (zh) * 2015-09-08 2019-08-09 Sillajen, Inc. 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
EP3432863A4 (en) * 2016-03-25 2019-11-13 University of Pittsburgh - of The Commonwealth System of Higher Education SYNTHETICALLY COVED VIRUS
EP3254692A1 (en) * 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
AU2017298385A1 (en) 2016-07-19 2019-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses targeting STAT3
WO2018057755A1 (en) * 2016-09-21 2018-03-29 Thorne Stephen H High mobility group box i mutant
GB201616365D0 (en) 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
AU2018215558B2 (en) * 2017-02-03 2023-05-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
WO2018165161A1 (en) * 2017-03-06 2018-09-13 Novartis Ag Methods and compositions for determining the potency of a therapeutic cellular composition
AU2018254626B2 (en) * 2017-04-21 2023-12-21 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2019106205A1 (en) 2017-12-01 2019-06-06 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
MX2020007010A (es) 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
US20220370527A1 (en) * 2018-07-20 2022-11-24 Ansun Biopharma, Inc. Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
JP2022516006A (ja) * 2018-12-21 2022-02-24 オタワ ホスピタル リサーチ インスティチュート 修飾オルソポックスウイルスベクター
CN113661236A (zh) * 2019-01-07 2021-11-16 卡利威尔免疫治疗公司 治疗癌症的方法
WO2020148612A1 (en) * 2019-01-14 2020-07-23 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CA3129883A1 (en) * 2019-02-14 2020-08-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CN120037270A (zh) * 2019-08-26 2025-05-27 拜耳诺克斯有限公司 包含痘苗病毒和羟基脲作为活性成分的用于治疗癌症的药物组合物
EP4045657A4 (en) * 2019-10-16 2023-11-15 KaliVir Immunotherapeutics, Inc. MODIFIED EXTRACELLULAR ENCLOSED VIRUS
EP4061417A4 (en) * 2019-11-20 2023-10-11 University of Pittsburgh - of the Commonwealth System of Higher Education VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CA3163805A1 (en) * 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
AU2021205287A1 (en) * 2020-01-09 2022-07-21 Pfizer Inc. Recombinant vaccinia virus
CA3170045A1 (en) * 2020-03-06 2021-09-10 Saumendra N. SARKAR Irf modulator-expressing oncolytic viruses for treating cancer
EP4172323A1 (en) * 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL316712B2 (en) * 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
KR20240026507A (ko) * 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
CN120676952A (zh) * 2022-07-08 2025-09-19 维罗米梭公司 溶瘤痘苗病毒及其重组病毒和使用方法
WO2025251079A1 (en) * 2024-05-31 2025-12-04 University Of Massachusetts Rna compositions and methods of use thereof in the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9305855A (es) 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
WO2000073479A1 (en) 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
WO2007023725A1 (ja) * 2005-08-25 2007-03-01 Yokohama City University 遺伝子ワクチン
AU2012244210B2 (en) * 2005-09-07 2014-10-02 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CN101351213B (zh) 2005-09-07 2013-10-02 詹纳里克斯公司 使用表达gm-csf的痘病毒系统性治疗转移性癌和/或全身散布性癌
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2009124044A2 (en) * 2008-03-31 2009-10-08 University Of Florida Research Foundation, Inc. Tumor growth inhibition via conditioning of tumor microenvironment
ES2671570T3 (es) 2009-09-14 2018-06-07 Sillajen Biotherapeutics, Inc. Terapia combinada contra el cáncer con virus oncolítico de vaccinia
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
CN114262690A (zh) * 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
AU2014308648B2 (en) 2013-08-22 2020-11-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-oncolytic therapies

Also Published As

Publication number Publication date
JP7333431B2 (ja) 2023-08-24
JP6912199B2 (ja) 2021-08-04
EP3778897A1 (en) 2021-02-17
HRP20240078T1 (hr) 2024-03-29
JP2019205451A (ja) 2019-12-05
SG11201600960PA (en) 2016-03-30
PE20160673A1 (es) 2016-07-21
WO2015027163A9 (en) 2016-04-14
JP2016527920A (ja) 2016-09-15
EA201690444A1 (ru) 2016-08-31
EA037582B1 (ru) 2021-04-16
AU2014308648B2 (en) 2020-11-12
ES2971528T3 (es) 2024-06-05
US11478518B2 (en) 2022-10-25
CA3213715A1 (en) 2015-02-26
EP3036329B1 (en) 2020-10-07
MD4748C1 (ro) 2021-09-30
US20160235793A1 (en) 2016-08-18
ES2847305T3 (es) 2021-08-02
EP3036329A1 (en) 2016-06-29
MD4748B1 (ro) 2021-02-28
RS65104B1 (sr) 2024-02-29
FI3778897T3 (fi) 2024-01-25
LT3778897T (lt) 2024-02-12
WO2015027163A1 (en) 2015-02-26
CA2921041C (en) 2023-10-31
MD20160027A2 (ro) 2016-08-31
MD20180086A2 (ro) 2019-03-31
KR20160044529A (ko) 2016-04-25
PL3778897T3 (pl) 2024-04-02
MX2016002257A (es) 2016-11-08
US12514888B2 (en) 2026-01-06
JP7021154B2 (ja) 2022-02-16
DK3036329T3 (da) 2021-01-11
CN105658795B (zh) 2020-07-03
SMT202400047T1 (it) 2024-03-13
JP2022062171A (ja) 2022-04-19
CN105658795A (zh) 2016-06-08
AU2014308648A1 (en) 2016-03-03
CA2921041A1 (en) 2015-02-26
EP3036329A4 (en) 2017-08-02
HK1223402A1 (zh) 2017-07-28
EP4324918A2 (en) 2024-02-21
KR102389240B1 (ko) 2022-04-20
NZ716825A (en) 2022-02-25
CA3213683A1 (en) 2015-02-26
PT3778897T (pt) 2024-02-01
SI3778897T1 (sl) 2024-03-29
EP4324918A3 (en) 2024-04-24
MD4624B1 (ro) 2019-03-31
CY1126587T1 (el) 2026-02-25
MD4624C1 (ro) 2019-10-31
IL243996A0 (en) 2016-04-21
PH12016500329A1 (en) 2016-05-02
US20230008089A1 (en) 2023-01-12
EP3778897B1 (en) 2023-12-20
HUE066593T2 (hu) 2024-08-28

Similar Documents

Publication Publication Date Title
DK3036329T3 (da) Immunonkolytiske terapier
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
LT3038654T (lt) Naujas panaudojimas
PT3055308T (pt) Resumo
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
FI10138U1 (fi) Kelkkateltta
ES1078715Y (es) Mosquitera
DE112014005422A5 (de) Friktionsfalschdrallaggregat
BR112016000501A2 (pt) Nalador
ES1100380Y (es) Trompo